Search results for "therapeutic use"

showing 10 items of 104 documents

Extrahepatic Morbidity and Mortality of Chronic Hepatitis C

2015

Chronic hepatitis C virus (HCV) infection is associated with several extra-hepatic manifestations. Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from cutaneous and visceral vasculitis to glomerulonephritis and B cell non-Hodgkin’s lymphoma. HCV-infected patients have increased rates of insulin resistance, diabetes and atherosclerosis, which may lead to increased cardiovascular morbidity and mortality. Neurologic manifestations of HCV infection include fatigue and cognitive impairment. The mechanisms causing the extra-hepatic effects of HCV infection are likely multifactorial and may include endocrine effects, HCV replication in extra-hepatic cells, or a heig…

VasculitisLymphomaGlomerulonephritis/epidemiology/virologyLymphoma/epidemiology/virologyHepatitis C virusAlpha interferonHepacivirusddc:616.07Cryoglobulinemia/epidemiology/virologymedicine.disease_causeAntiviral AgentsAntiviral Agents/administration & dosage/pharmacology/therapeutic useHepacivirus/drug effects/pathogenicityLiver diseasechemistry.chemical_compoundGlomerulonephritisDiabetes mellitusRibavirinmedicineHumansGlucose Metabolism Disorders/epidemiology/virologyInterferon alfaGlucose Metabolism Disordersddc:616Hepatologybusiness.industryHepatitis C Chronic/drug therapy/epidemiology/immunology/mortality/virologyRibavirinVasculitis/epidemiology/virologyGastroenterologyInterferon-alphavirus diseasesHepatitis C Chronicmedicine.diseaseCryoglobulinemiadigestive system diseasesCryoglobulinemiachemistryRibavirin/pharmacology/therapeutic useHCVImmunologyMorbiditybusinessVasculitisInterferon-alpha/pharmacology/therapeutic usemedicine.drugGastroenterology
researchProduct

Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients.

2009

Comment in Timing of antihypertensive therapy and circadian blood pressure pattern. [Hypertension. 2009] Timing of antihypertensive therapy and circadian blood pressure pattern. Almirall J, Martínez-Ocaña JC, Comas L. Hypertension. 2009 Jun; 53(6):e41; author reply e42. Epub 2009 May 4. Dipping comes of age: the importance of nocturnal blood pressure. [Hypertension. 2009]. Dipping comes of age: the importance of nocturnal blood pressure. O'Brien E. Hypertension. 2009 Mar; 53(3):446-7. Epub 2009 Jan 26.Nondipping in patients with hypertension. [Hypertension. 2009] Ambulatory blood pressure (BP) monitoring has become useful in the diagnosis and management of hypertensive individuals. In addit…

cardiovascular risk factorsMale:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Cardiovascular Agents::Antihypertensive Agents [Medical Subject Headings]Blood Pressure:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Cohort Studiescircadian blood pressure patternFactores de riesgo cardiovascularPrevalenceRegistries:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]Blood Pressure Monitoring AmbulatoryMiddle AgedCircadian Rhythm:Phenomena and Processes::Physiological Phenomena::Chronobiology Phenomena::Periodicity::Circadian Rhythm [Medical Subject Headings]AmbulatoryHypertension:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Monitoring Physiologic::Monitoring Ambulatory::Blood Pressure Monitoring Ambulatory [Medical Subject Headings]CardiologyFemaleCohort studyAdultmedicine.medical_specialtyAmbulatory blood pressurenocturnal blood pressure dip:Check Tags::Male [Medical Subject Headings]:Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings]Diabetes mellitusInternal medicine:Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Blood Pressure [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]Internal MedicinemedicineHumansCircadian rhythm:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Linear Models [Medical Subject Headings]Risk factorAntihypertensive AgentsAgedbusiness.industrymedicine.diseaseObesitySurgerycircadianBlood pressure:Check Tags::Female [Medical Subject Headings]Spain:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings]Linear Models:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings]businessHypertension (Dallas, Tex. : 1979)
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

MORBILIDAD PSÍQUICA, EXISTENCIA DE DIAGNÓSTICO Y CONSUMO DE PSICOFÁRMACOS. DIFERENCIAS POR COMUNIDADES AUTÓNOMAS SEGÚN LA ENCUESTA NACIONAL DE SALUD …

2010

Background: Most of the studies on sychological distress in Spain have been conducted in small geographical areas or specific population groups. However, there are no studies that provide representative data for each Autonomous Community (AC). The objectives of this paper are to determine, both in Spain and in the AC, the prevalence of psychological distress, diagnosis, use of psychoactive medication, social support and self-perceived health, as well as to study the association between psychological distress and the rest of the variables. Methods: Cross-sectional study, using data from the 2006 National Health Survey, that was completed by 29,478 persons. Variables studied: sociodemographic…

medicine.medical_specialtyCross-sectional study:Psychiatry and Psychology::Mental Disorders [Medical Subject Headings]TerapéuticaPrevalencelcsh:MedicineTherapeuticsEncuestas de Atención de la SaludHealth Services Accessibility:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Health Care Surveys [Medical Subject Headings]Salud mentalSocial supportDiagnosisAccesibilidad a los servicios de saludEpidemiologyHealth carePrevalencemedicineMedical prescriptionPsychiatryTerapeúticaMental disorder diagnosis:Health Care::Health Care Quality Access and Evaluation::Delivery of Health Care::Health Services Accessibility [Medical Subject Headings]:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]business.industryDiagnósticolcsh:Public aspects of medicinelcsh:Rlcsh:RA1-1270General Medicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Central Nervous System Agents::Psychotropic Drugs [Medical Subject Headings]Mental healthMental HealthHealth Care SurveysSmall-Area Analysis:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]PrevalenciabusinessRevista Española de Salud Pública
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic L…

2019

OBJECTIVE: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRIc SLE ). METHODS: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRIc SLE and rate a total of 433 unique patient profiles for the presence/absence of CRIc SLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Eryt…

medicine.medical_specialtyOutcome AssessmentHealth Care/methodsAdolescentDelphi TechniqueAntirheumatic Agents/therapeutic useSeverity of Illness IndexChild healthArticle03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineSeverity of illnessOutcome Assessment Health CaremedicinePediatric nephrologyHumansLupus Erythematosus Systemicskin and connective tissue diseasesChild030203 arthritis & rheumatologySystemic lupus erythematosusLupus erythematosusLupus ErythematosusReceiver operating characteristicbusiness.industryConsensus conferencechildhood-onset systemic lupus erythematosusOutcome Assessment Health Care/methodsmedicine.diseaseRheumatologyRheumatologySystemic lupus erythematosusautoimmune inflammatory diseaseAntirheumatic AgentsLupus Erythematosus Systemic/drug therapySystemic/drug therapybusinessAlgorithmsArthritis Care and Research
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Women, thrombosis, and cancer: A gender-specific analysis.

2017

Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPregnancy Complications CardiovascularLow molecular weight heparin030204 cardiovascular system & hematologyPregnancy Complications Cardiovascular/drug therapy/epidemiology03 medical and health sciences0302 clinical medicinePregnancyRisk FactorsInternal medicineNeoplasmsAntithromboticMedicineHumanscardiovascular diseasesddc:616Venous Thromboembolism/drug therapy/epidemiologybusiness.industryAromatase InhibitorsAnticoagulantCancerAnticoagulantsThrombosisHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesThrombosisNeoplasms/complications/epidemiologySurgeryPostmenopauseVenous thrombosisAnticoagulants/therapeutic use030220 oncology & carcinogenesisFemaleHormone therapybusinessComplicationPregnancy Complications NeoplasticPregnancy Complications Neoplastic/epidemiologyThrombosis/drug therapy/epidemiologyAromatase Inhibitors/therapeutic useThrombosis research
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct